However, reassessment with IRSN-23 two weeks after treatment initiation revealed significantly improved pCR rates in the Gp-R group, This suggests that IRSN-23 may be more sensitive to dynamic changes in the tumor microenvironment during treatment, particularly in response to anti-HER2 therapies. This evidence concerns the gene ALDH18A1 and neoplasm.